Medical Oncology

, Volume 29, Issue 2, pp 1197–1201

Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure

Case Report

DOI: 10.1007/s12032-011-9938-4

Cite this article as:
Gharwan, H. & Truica, C.I. Med Oncol (2012) 29: 1197. doi:10.1007/s12032-011-9938-4


We report a case of kappa light chain deposition disease (LCDD) associated with multiple myeloma in a patient presenting with acute renal failure, 2+ proteinuria and hypercalcemia. Serum protein electrophoresis showed an M-spike at 0.1 g/dL. 24-h urine protein electrophoresis showed Bence-Jones proteinuria of 3.8 g. Serum-free light chain assay found excess kappa chains at 3080 mg/L, with normal lambda and an elevated kappa:lambda ratio of 124.7. A kidney biopsy revealed kappa light chain nephropathy with PAS-negative tubular casts in the cortex and outer medulla. Bone marrow biopsy showed 15% kappa-restricted plasma cells. Serum beta-2 microglobulin level was elevated at 7.94 mg/dL. The patient received a 3-day course of plasmapheresis followed by eight cycles of bortezomib (Velcade®), liposomal doxorubicin, and dexamethasone (VDD) and did not require hemodialysis. As partial response was not achieved, treatment was continued with three cycles of bortezomib, cyclophosphamide, dexamethasone, and thalidomide, followed by thalidomide maintenance at 100 mg daily. Thirty-two months after the diagnosis, the patient’s renal function was improved and he achieved a partial response. This case underlines the feasibility and effectiveness of bortezomib-based chemotherapy in the treatment of LCDD with severe renal dysfunction.


Light chain deposition disease Kappa Lambda Renal failure Bortezomib 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Johns Hopkins University/Sinai Hospital Program of Internal MedicineBaltimoreUSA
  2. 2.Alvin and Lois Lapidus Cancer Institute, Sinai HospitalBaltimoreUSA

Personalised recommendations